CLINICAL_TRIALS
trial_result
· 2018-08-22
Clinical Trial Update: A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures. [Phase 2]
Summary
Phase 2 dose-ranging study of brivaracetam in patients with refractory partial onset seizures completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UCB Pharma | Conditions: Epilepsy | Phase 2 | Status: COMPLETED | Results posted: 2018-08-22